Weight-loss drugs are already dropping in price; could they go even lower?
The price of weight loss drugs is falling, making them more accessible to consumers, and the price could get driven even lower.
Highly sought-after drugs like Wegovy and Zepbound both retail at roughly $1,000 each and have been difficult for people without insurance to obtain.
Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from $650 to $499 for uninsured patients or people without coverage. The drug's list price of $1,349 has remained unchanged.
Meanwhile, Eli Lilly reduced Zepbound's starter dose to $349 and higher doses to $499 after launching a self-pay program called Lilly Direct. The new doses require patients to manually draw medication from a vial with a syringe.
In prior years, people would pay about $1,500 a month for the drugs, but in recent months have been able to obtain the doses for roughly $400 to $500, according to NBC News.
A May 2024 survey from the health policy group KFF found that half of U.S. adults say it's difficult to afford the medication.
Pressure from Congress and increased competition are some of the factors that led the drugmakers to reduce the cost. This has led to patients paying less out of pocket because they can afford the cheaper prices or their insurance now covers the drugs. More insurance plans have allowed for the drugs because they have been proven to treat heart disease risk and obstructive sleep apnea.
This month, a study published in the New England Journal of Medicine found Zepbound outperformed Wegovy in a head-to-head clinical trial.
Dr David Rind, a primary care physician and the chief medical officer for the Institute for Clinical and Economic Review, told NBC News: 'You're talking $6,000 a year, and that is still probably more than insurers are paying right now.'
He continued: 'If insurance is relying on the fact that not covering it will allow people to buy it out of pocket, as a primary care doctor, I have a lot of concerns about that...For all my complaining about the price, these are drugs that we should want to give to lots of people, but it's been really hard to see how we can afford them.'
But Rind said not to expect dramatic price drops in the foreseeable future. He said those cuts are likely to come when other weight-loss drugs being developed are approved, which could take several years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
Class Action Announcement HIMS: A Securities Fraud Class Action Lawsuit Was Filed Against Hims & Hers Health, Inc. (HIMS)
RADNOR, PA - June 29, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. THE LEAD PLAINTIFF PROCESS: Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. 280 King of Prussia Road Radnor, PA 19087 (484) 270-1453 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
USA Today
4 hours ago
- USA Today
NYC mayoral candidate Mamdani says ‘I don't think we should have billionaires'
The progressive candidate's comments come days after his presumptive victory in the Democratic primary over former Gov. Andrew Cuomo. Zohran Mamdani, the winner of the Democratic primary to be mayor of New York City, told NBC News' 'Meet the Press' on June 29 that he doesn't believe billionaires should exist. Mamdani, a self-identified democratic socialist, was asked directly whether 'billionaires have a right to exist' and he responded: 'I don't think we should have billionaires because frankly it is so much money in a moment of such inequality.' The political upstart's comments come days after his shocking Democratic primary victory over former New York Governor Andrew Cuomo. Mamdani campaigned on a radical vision of remaking a city seen by many as the mecca of the world's rich and powerful. 'Ultimately what we need more of is equality across the city and across the state and country,' Mamdani told Meet the Press. 'I look forward to working with everyone including billionaires to make a city that is fair for all of us.' His comments on the richest of the rich come as some of his closest allies, U.S. Rep. Alexandria Ocasio Cortez and Sen. Bernie Sanders, travel across the U.S. on their 'fighting oligarchy' tour. The New York state Assembly member's platform excited progressives with plans that included promises to freeze rents in regulated apartments and make buses free. He also supports a 2% tax on residents earning above $1 million annually and raising the corporate tax rate to 11.5%. But he wouldn't have the authority to raise taxes as mayor. Mamdani, 33, has not stated a plan to take money from billionaires. The young left-wing candidate's ascendancy spooked rich, politically-active donors. A Super PAC backing Cuomo spent $24 million, much of it raised from Trump donors such as hedge fund manager Bill Ackman and real estate executive Steven Roth, along with former New York City Mayor Michael Bloomberg. Cuomo is expected to remain on the ballot for mayor in November, USA TODAY previously reported. Current Mayor Eric Adams will also run against Mamdani as an independent.
The Hill
12 hours ago
- The Hill
Murphy says he thinks ‘there's a chance' Trump's megabill doesn't pass
Sen. Chris Murphy (D-Conn.) said Sunday he believed 'there's a chance' President Trump's 'big, beautiful bill' will not achieve Senate passage. 'Senator Murphy, do you think there's any chance that the so-called 'big, beautiful bill' does not pass the Senate?' NBC News's Kristen Welker asked Murphy on 'Meet the Press.' 'I do think there's a chance it doesn't pass. They are trying to ram it through as quickly as they can, likely in the middle of the night tonight, because every day that this bill hangs out there, it becomes less popular,' Murphy replied. 'As you noted, by almost a two-to-one margin, the American people hate this piece of legislation, because it's going to represent the biggest transfer of wealth and money from the poor and the middle class to the rich in the history of the country,' he added. Senate Republicans on Saturday narrowly voted to advance a nearly 1,000-page bill to implement Trump's agenda despite opposition from two of their members. Sens. Rand Paul (R-Ky.) and Thom Tillis (R-N.C.) both voted against advancing the package. Paul has opposed a provision to increase the debt limit by $5 trillion, while Tillis has said the bill would cost North Carolina $38.9 trillion in federal Medicaid funding. 'I cannot support this bill in its current form. It would result in tens of billions of dollars in lost funding for North Carolina, including our hospitals and rural communities,' Tillis said in a prior statement. 'This will force the state to make painful decisions like eliminating Medicaid coverage for hundreds of thousands in the expansion population, and even reducing critical services for those in the traditional Medicaid population,' he added.
